About MannKind

MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas.

• First, we are continuing to execute the Technosphere® Insulin clinical trial program.
• Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
• Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.